Krensavage Asset Management, LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Krensavage Asset Management, LLC reported 12 stock positions worth $225.5 million. Its top holding was Exelixis (EXEL) at 16.5% of the portfolio, followed by United Therapeutics (UTHR, 16.0%) and Biogen (BIIB, 12.8%). Compared with Q4 2023, it opened 1 new position, sold out of 1, added to 4 and reduced 7. The biggest buy was Enanta Pharmaceuticals (ENTA, shares +51%) and the biggest sale Regeneron Pharmaceuticals (REGN, shares −74%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001609251
- Portfolio Value
- $225.5M (Q1 2024)
- SEC Filing
- 0001609251-24-000005 ↗ filed May 15, 2024
Holdings Value
Holdings 12 stocks · $225.5M
| EXEL Exelixis Inc. | 16.48% | 1,566,140 | $37.2M | Reduce -17.5% |
| UTHR United Therapeutics Corp. | 15.96% | 156,714 | $36.0M | Reduce -22.0% |
| BIIB Biogen Inc. | 12.82% | 134,068 | $28.9M | Reduce -16.5% |
| TARO Taro Pharmaceutical Indus | 12.16% | 647,868 | $27.4M | Add +0.2% |
| CAH Cardinal Health Inc. | 11.69% | 235,656 | $26.4M | Reduce -16.3% |
| ENTA Enanta Pharmaceuticals Inc. | 8.71% | 1,124,586 | $19.6M | Add +51.4% |
| JAZZ Jazz Pharmaceuticals PLC | 5.40% | 101,151 | $12.2M | Add +1.1% |
| REGN Regeneron Pharmaceuticals | 5.33% | 12,494 | $12.0M | Reduce -73.6% |
| BNTX Biontech SE-ADR | 4.91% | 120,000 | $11.1M | New |
| SNY Sanofi-ADR | 3.25% | 150,959 | $7.3M | Add +0.4% |
| ALKS Alkermes PLC | 3.09% | 257,554 | $7.0M | Reduce -72.0% |
| MURA Mural Oncology PLC | 0.19% | 88,001 | $430K | Reduce -3.1% |
Portfolio Sells Q4 2023 → Q1 2024
| REGN Regeneron Pharmaceuticals | Reduce -73.6% | 5.33% | −9.39 |
| ALKS Alkermes PLC | Reduce -72.0% | 3.09% | −5.94 |
| BIIB Biogen Inc. | Reduce -16.5% | 12.82% | −1.92 |
| MASI Masimo Corp. | Sold out | 0.00% | −0.33 |
| MURA Mural Oncology PLC | Reduce -3.1% | 0.19% | −0.00 |
| UTHR United Therapeutics Corp. | Reduce -22.0% | 15.96% | +0.29 |
| EXEL Exelixis Inc. | Reduce -17.5% | 16.48% | +0.32 |
| CAH Cardinal Health Inc. | Reduce -16.3% | 11.69% | +1.63 |
Portfolio Buys Q4 2023 → Q1 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 18 | $263.2M | ENTA, JAZZ, UTHR, BMRN, EXEL |
| Q1 2026 | 20 | $255.7M | UTHR, ENTA, JAZZ, BMRN, EXEL |
| Q4 2025 | 18 | $283.1M | UTHR, ENTA, BMRN, JAZZ, EXEL |
| Q3 2025 | 17 | $234.7M | UTHR, ENTA, JAZZ, BMRN, EXEL |
| Q2 2025 | 15 | $188.9M | UTHR, CAH, EXEL, JAZZ, ENTA |
| Q1 2025 | 14 | $180.9M | EXEL, UTHR, CAH, SUPN, JAZZ |
| Q4 2024Amended | 12 | $169.0M | UTHR, EXEL, CAH, BIIB, JAZZ |
| Q3 2024 | 13 | $178.5M | UTHR, EXEL, CAH, BIIB, ENTA |
| Q2 2024 | 13 | $217.8M | EXEL, UTHR, BIIB, TARO, CAH |
| Q1 2024 | 12 | $225.5M | EXEL, UTHR, BIIB, TARO, CAH |